STERIS (NYSE:STE) Issues FY 2026 Earnings Guidance

STERIS (NYSE:STE) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 10.150-10.300 for the period, compared to the consensus EPS estimate of 10.220. The company issued revenue guidance of $5.9 billion-$6.0 billion, compared to the consensus revenue estimate of $5.9 billion.

STERIS Stock Up 1.1%

NYSE:STE traded up $2.81 during mid-day trading on Wednesday, reaching $264.48. The company’s stock had a trading volume of 852,757 shares, compared to its average volume of 525,878. STERIS has a 1 year low of $204.90 and a 1 year high of $269.44. The stock has a fifty day moving average of $259.17 and a 200-day moving average of $249.54. The firm has a market capitalization of $25.96 billion, a PE ratio of 38.00 and a beta of 1.03. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.07% and a return on equity of 14.43%. During the same quarter in the prior year, the business posted $2.32 EPS. The firm’s revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities research analysts forecast that STERIS will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a dividend of $0.63 per share. The ex-dividend date is Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. STERIS’s dividend payout ratio is currently 36.21%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $275.20.

Insider Transactions at STERIS

In other news, VP Julia Madsen sold 5,008 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the transaction, the vice president owned 10,710 shares in the company, valued at $2,806,020. This represents a 31.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of STERIS stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total transaction of $1,297,021.80. Following the completion of the sale, the vice president owned 5,695 shares of the company’s stock, valued at $1,466,747.25. This trade represents a 46.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 25,044 shares of company stock worth $6,586,218. Insiders own 1.07% of the company’s stock.

Hedge Funds Weigh In On STERIS

Hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in STERIS by 34.9% during the 2nd quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 45 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in shares of STERIS by 2.4% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 2,261 shares of the medical equipment provider’s stock worth $560,000 after purchasing an additional 53 shares during the last quarter. Fiduciary Trust Co lifted its holdings in shares of STERIS by 0.9% during the third quarter. Fiduciary Trust Co now owns 6,785 shares of the medical equipment provider’s stock worth $1,679,000 after purchasing an additional 61 shares during the period. Quadrant Capital Group LLC boosted its position in STERIS by 3.2% in the third quarter. Quadrant Capital Group LLC now owns 2,429 shares of the medical equipment provider’s stock valued at $601,000 after buying an additional 75 shares during the last quarter. Finally, Gallagher Fiduciary Advisors LLC boosted its position in STERIS by 5.0% in the second quarter. Gallagher Fiduciary Advisors LLC now owns 2,153 shares of the medical equipment provider’s stock valued at $517,000 after buying an additional 102 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.